The DOI matches its Crossref record; the references it cites are not checked yet.
Results of a Prospective Trial to Compare 68Ga-DOTA-TATE with SiPM-Based PET/CT vs. Conventional PET/CT in Patients with Neuroendocrine Tumors
Open accessAbstract
We prospectively enrolled patients with neuroendocrine tumors (NETs). They underwent a single 68Ga-DOTA-TATE injection followed by dual imaging and were randomly scanned using first either the conventional or the silicon photomultiplier (SiPM) positron emission tomography/computed tomography (PET/CT), followed by imaging using the other system. A total of 94 patients, 44 men and 50 women, between 35 and 91 years old (mean ± SD: 63 ± 11.2), were enrolled. Fifty-two out of ninety-four participants underwent SiPM PET/CT first and a total of 162 lesions were detected using both scanners. Forty-two out of ninety-four participants underwent conventional PET/CT first and a total of 108 lesions were detected using both scanners. Regardless of whether SiPM-based PET/CT was used first or second, maximum standardized uptake value (SUVmax) of lesions measured on SiPM was on average 20% higher when comparing two scanners with all enrolled patients, and the difference was statistically significant. SiPM-based PET/CT detected 19 more lesions in 13 patients compared with conventional PET/CT. No lesions were only identified by conventional PET/CT. In conclusion, we observed higher SUVmax for lesions measured from SiPM PET/CT compared with conventional PET/CT regardless of the order of the scans. SiPM PET/CT allowed for identification of more lesions than conventional PET/CT. While delayed imaging can lead to higher SUVmax in cancer lesions, in the series of lesions identified when SiPM PET/CT was used first, this was not the case; therefore, the data suggest superior performance of the SiPM PET/CT scanner in visualizing and quantifying lesions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Baratto et al. found higher lesion detection rates in 13 of 94 patients with [68Ga]Ga-DOTATATE using SiPM vs PMT PET/CT in randomized order.
“Similarly, Baratto et al. found higher lesion detection rates in 13 of 94 patients with [68Ga]Ga-DOTATATE using SiPM vs. PMT PET/CT in randomized order (SiPM, 20 cm axial FOV; PMT, 15.7 cm) [155].”
From Influences on PET Quantification and Interpretation (2022) · cites this paper as [155]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists haven’t been fetched yet
References 15 · Cited by 6
Research works printed but not linked: 14
- Boellaard, 2015, FDG PET/CT: EANM procedure guidelines for tumour imaging: Version 2.0, Eur. J. Nucl. Med. Mol. Imaging, 42, 328, 10.1007/s00259-014-2961-x · DOI · Paper page
- Jadvar, 2017, Appropriate Use Criteria for (18)F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease, J. Nucl. Med., 58, 2026, 10.2967/jnumed.117.197988 · DOI
- Hope, 2018, Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors, J. Nucl. Med., 59, 66, 10.2967/jnumed.117.202275 · DOI
- Virgolini, 2010, Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE, Eur. J. Nucl. Med. Mol. Imaging, 37, 2004, 10.1007/s00259-010-1512-3 · DOI
- Spanoudaki, 2010, Photo-detectors for time of flight positron emission tomography (ToF-PET), Sensors, 10, 10484, 10.3390/s101110484 · DOI
- Koopman, 2017, Quantification, improvement, and harmonization of small lesion detection with state-of-the-art PET, Eur. J. Nucl. Med. Mol. Imaging, 44, 4, 10.1007/s00259-017-3727-z · DOI
- Levin, 2016, Design Features and Mutual Compatibility Studies of the Time-of-Flight PET Capable GE SIGNA PET/MR System, IEEE Trans. Med. Imaging, 35, 1907, 10.1109/TMI.2016.2537811 · DOI
- Baratto, L., Park, S.Y., Hatami, N., Davidzon, G., Srinivas, S., Gambhir, S.S., and Iagaru, A. (2017). 18F-FDG silicon photomultiplier PET/CT: A pilot study comparing semi-quantitative measurements with standard PET/CT. PLoS ONE, 12. · DOI
- Lantos, 2018, Standard OSEM vs. regularized PET image reconstruction: Qualitative and quantitative comparison using phantom data and various clinical radiopharmaceuticals, Am. J. Nucl. Med. Mol. Imaging, 8, 110
- Kitajima, 2010, Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence, Eur. J. Nucl. Med. Mol. Imaging, 37, 1490, 10.1007/s00259-010-1440-2 · DOI
- Flotats, 2019, Digital vs. analog PET/CT: Intra-subject comparison of the SUVmax in target lesions and reference regions, Eur. J. Nucl. Med. Mol. Imaging, 46, 1745, 10.1007/s00259-018-4256-0 · DOI · Paper page
- Flotats, 2019, Comparison of image quality and lesion detection between digital and analog PET/CT, Eur. J. Nucl. Med. Mol. Imaging, 46, 1383, 10.1007/s00259-019-4260-z · DOI · Paper page
- Torabi, 2004, Current concepts in lymph node imaging, J. Nucl. Med., 45, 1509
- Baratto, 2020, The Effect of Various beta Values on Image Quality and Semiquantitative Measurements in 68Ga-RM2 and 68Ga-PSMA-11 PET/MRI Images Reconstructed with a Block Sequential Regularized Expectation Maximization Algorithm, Clin. Nucl. Med., 45, 506, 10.1097/RLU.0000000000003075 · DOI
Metadata
- Authors
- Baratto, L., Toriihara, A., Hatami, N., Aparici, C. M., Davidzon, G., Levin, C. S., & Iagaru, A.
- Affiliations
- Stanford Medicine (US)
- Asahi General Hospital (JP)
- Corresponding author
- Baratto, Lucia
- Toriihara, Akira
- Venue
- Diagnostics
- Publisher
- MDPI AG
- Published
- 2021-05-30
- Volume
- 11
- Issue
- 6
- Pages
- 992
- ISSN
- 2075-4418 (ISSN-L)
- PMC
- PMC8228776
- OpenAlex
- W3164661563
- Cited by
- 6
- References
- 15
- Citations by year
- 2024: 2 · 2023: 1 · 2022: 3
- FWCI
- 0.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diagnostics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Detection and Scintillator Technologies
- Keywords
- 68Ga-DOTATATE, neuroendocrine tumors, SUVmax, lesion detection, gallium-68 radiotracer, delayed imaging
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
